Nicole C A J Van De Kar

List of Publications by Year
in descending order

81 papers	3,458 citations	201674 27 h-index	144013 57 g-index
88 all docs	88 docs citations	88 times ranked	2803 citing authors

#	Article	IF	Citations
1	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	1.7	445
2	Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric Nephrology, 2009, 24, 687-696.	1.7	315
3	Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney International, 2016, 89, 701-711.	5.2	210
4	Effects of TNFÎ± on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney International, 1997, 51, 1245-1256.	5.2	182
5	Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatric Nephrology, 2012, 27, 1283-1291.	1.7	135
6	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatric Nephrology, 2014, 29, 1967-1978.	1.7	95
7	Increased Arterial Stiffness in Young Adults with End-Stage Renal Disease since Childhood. Journal of the American Society of Nephrology: JASN, 2002, 13, 2953-2961.	6.1	93
8	Epidemiology, Clinical Presentation, and Pathophysiology of Atypical and Recurrent Hemolytic Uremic Syndrome. Seminars in Thrombosis and Hemostasis, 2006, 32, 113-120.	2.7	91
9	Mutation analysis and clinical implications of von Willebrand factorâ€“cleaving protease deficiency. Kidney International, 2003, 63, 1995-1999.	5.2	83
10	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2019, 58, 859-874.	3.5	82
11	Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrology Dialysis Transplantation, 2010, 25, 2195-2202.	0.7	79
12	Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatric Nephrology, 2005, 20, 374-379.	1.7	66
13	Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrology Dialysis Transplantation, 2014, 29, iv131-iv141.	0.7	65
14	Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatric Nephrology, 2019, 34, 2261-2277.	1.7	60
15	Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives. Microbiology Spectrum, 2014, 2, EHEC-0025-2014.	3.0	51
16	Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatric Nephrology, 2017, 32, 297-309.	1.7	48
17	Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. American Journal of Kidney Diseases, 2017, 70, 770-777.	1.9	46
18	Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. Journal of Human Genetics, 2012, 57, 459-464.	2.3	43

#	Article	IF	Citations
19	Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology, 2015, 160, 237-243.	3.2	42
20	Refractory thrombotic thrombocytopenic purpura in a 16â€yearâ€old girl: successful treatment with bortezomib. European Journal of Haematology, 2014, 92, 80-82.	2.2	40
21	Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatric Nephrology, 2012, 27, 1519-1524.	1.7	38
22	Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrology Dialysis Transplantation, 2018, 33, 635-645.	0.7	36
23	Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2015, 65, 342.	1.9	35
24	A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatric Nephrology, 2007, 22, 371-375.	1.7	33
25	The genetics of atypical hemolytic uremic syndrome. Medizinische Genetik, 2018, 30, 400-409.	0.2	33
26	Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatric Nephrology, 2012, 27, 1193-1195.	1.7	31
27	Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases. Frontiers in Immunology, 2018, 9, 612.	4.8	30
28	Fecal diagnostics in combination with serology: best test to establish STEC-HUS. Pediatric Nephrology, 2016, 31, 2163-2170.	1.7	27
29	Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2. Pediatric Nephrology, 2017, 32, 1263-1268.	1.7	27
30	Adult Renal Size is Not a Suitable Marker for Nephron Numbers: An Individual Patient Data Meta-Analysis. Kidney and Blood Pressure Research, 2013, 37, 540-546.	2.0	21
31	Clinical and genetic analyses of a Dutch cohort of 40 patients with a nephronophthisis-related ciliopathy. Pediatric Nephrology, 2018, 33, 1701-1712.	1.7	20
32	Cat induced Pasteurella multocida peritonitis in peritoneal dialysis: A case report and review of the literature. International Journal of Hygiene and Environmental Health, 2013, 216, 211-213.	4.3	19
33	Verocytotoxin-producing Escherichia coli infection in household members of children with hemolytic-uremic syndrome in the Netherlands. Pediatric Infectious Disease Journal, 1999, 18, 709-714.	2.0	18
34	Local Fibrinolytic Therapy with Urokinase for Peritoneal Dialysis Catheter Obstruction in Children. Peritoneal Dialysis International, 2002, 22, 84-86.	2.3	17
35	Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo. Blood, 2015, 126, 278-279.	1.4	17
36	Complement Factor H Serum Levels Determine Resistance to Pneumococcal Invasive Disease. Journal of Infectious Diseases, 2016, 213, 1820-1827.	4.0	17

#	Article	IF	Citations
37	Human pluripotent stem cell-derived kidney organoids for personalized congenital and idiopathic nephrotic syndrome modeling. Development (Cambridge), 2022, 149, .	2.5	16
38	Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Therapeutic Advances in Hematology, 2015, 6, 171-185.	2.5	15
39	The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?. Pediatric Nephrology, 2019, 34, 1349-1367.	1.7	15
40	Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy. Frontiers in Immunology, 2019, 10, 1350.	4.8	15
41	Compound heterozygous mutations in the C6 gene of a child with recurrent infections. Molecular Immunology, 2014, 58, 201-205.	2.2	14
42	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient, 2017, 10, 629-642.	2.7	14
43	Refractory severe intestinal vasculitis due to Henoch-SchÃ¶nlein Purpura: successful treatment with plasmapheresis. Acta Paediatrica, International Journal of Paediatrics, 2006, 95, 622-623.	1.5	14
44	Diagnosis of abdominal aortic hypoplasia by state-of-the-art MR angiography. Pediatric Radiology, 2006, 36, 57-60.	2.0	11
45	Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient, 2019, 12, 149-162.	2.7	10
46	Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Frontiers in Immunology, 2020, 11, 612706.	4.8	9
47	A clinical approach to children with C3 glomerulopathy. Pediatric Nephrology, 2022, 37, 521-535.	1.7	9
48	Intraperitoneal treatment with darbepoetin for children on peritoneal dialysis. Pediatric Nephrology, 2007, 22, 436-440.	1.7	7
49	Severe infantile Bordetella pertussis pneumonia in monozygotic twins with a congenital C3 deficiency. European Journal of Pediatrics, 2014, 173, 1591-1594.	2.7	7
50	Glyco-iELISA: a highly sensitive and unambiguous serological method to diagnose STEC-HUS caused by serotype O157. Pediatric Nephrology, 2019, 34, 631-639.	1.7	7
51	The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment. Cellular and Molecular Immunology, 2020, 17, 653-655.	10.5	6
52	The potential of individualized dosing of ravulizumab to improve patientâ€friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs. British Journal of Clinical Pharmacology, 2021, 87, 3359-3363.	2.4	6
53	The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS. Microorganisms, 2021, 9, 2157.	3.6	6
54	Long-Term Effectiveness of Intraperitoneal Erythropoietin in Children on Nipd by Administration in Small Bags. Peritoneal Dialysis International, 2001, 21, 197-199.	2.3	5

#	Article	IF	Citations
55	Heme as Possible Contributing Factor in the Evolvement of Shiga-Toxin Escherichia coli Induced Hemolytic-Uremic Syndrome. Frontiers in Immunology, 2020, 11, 547406.	4.8	5
56	Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Immunology, 2021, 12, 715704.	4.8	5
57	Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal. CKJ: Clinical Kidney Journal, 2021, 14, 1939-1945.	2.9	5
58	The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway. Journal of Immunology, 2021, 207, 2465-2472.	0.8	5
59	Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome. Journal of Human Genetics, 2018, 63, 93-96.	2.3	4
60	Primary Human Derived Blood Outgrowth Endothelial Cells: An Appropriate In Vitro Model to Study Shiga Toxin Mediated Damage of Endothelial Cells. Toxins, 2020, 12, 483.	3.4	4
61	Preparing for a kidney transplant: Medical nephrectomy in children with nephrotic syndrome. Pediatric Transplantation, 2020, 24, e13703.	1.0	4
62	Enough is enough: targeted eculizumab withdrawal in atypical hemolytic uremic syndrome. Kidney International, 2021, 100, 265-268.	5.2	4
63	Shiga Toxin 2a Induces NETosis via NOX-Dependent Pathway. Biomedicines, 2021, 9, 1807.	3.2	4
64	Shiga Toxin Selectively Upregulates Expression of Syndecan-4 and Adhesion Molecule ICAM-1 in Human Glomerular Microvascular Endothelium. Toxins, 2020, 12, 435.	3.4	3
65	Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatric Nephrology, 2022, 37, 601-612.	1.7	3
66	Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrology Dialysis Transplantation, 2023, 38, 362-371.	0.7	3
67	Unexplained hypothermia and bradycardia in two pediatric patients with Wegenerâ€™s granulomatosis. Pediatric Nephrology, 2011, 26, 325-326.	1.7	2
68	Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy. American Journal of Kidney Diseases, 2018, 72, 906.	1.9	2
69	Cell Biological Responses after Shiga Toxin-1 Exposure to Primary Human Glomerular Microvascular Endothelial Cells from Pediatric and Adult Origin. International Journal of Molecular Sciences, 2021, 22, 5615.	4.1	2
70	Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity. Methods in Molecular Biology, 2021, 2227, 83-96.	0.9	2
71	Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update. Blood, 2014, 124, 4986-4986.	1.4	2
72	The challenge of managing hemophilia A and STEC-induced hemolytic uremic syndrome. Pediatric Nephrology, 2013, 28, 349-352.	1.7	1

#	Article	IF	Citations
73	Pharmacokinetics and pharmacodynamics of eculizumab in individualized treatment of atypical hemolytic uremic syndrome. Immunobiology, 2016, 221, 1141.	1.9	1
74	A young girl with an unusual cause of acute kidney injury: Answers. Pediatric Nephrology, 2016, 31, 2075-2078.	1.7	1
75	SaO018FACTOR D INHIBITION WITH ACH-4471 TO REDUCE COMPLEMENT ALTERNATIVE PATHWAY HYPERACTIVITY AND PROTEINURIA IN C3 GLOMERULOPATHY: PRELIMINARY PROOF OF CONCEPT DATA. Nephrology Dialysis Transplantation, 2018, 33, i322-i322.	0.7	1
76	Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury?. Pediatric Nephrology, 2020, 35, 1791-1795.	1.7	1
77	Drug-Drug Interactions in Treatment Using Azole Antifungal Agents. JAMA - Journal of the American Medical Association, 2016, 315, 2622.	7.4	0
78	A young girl with an unusual cause of acute kidney injury: Questions. Pediatric Nephrology, 2016, 31, 2071-2073.	1.7	0
79	Re: Bevill et al.: The Modern Metabolic Stone Evaluation in Children (Urology 2017;101:15-20). Urology, 2017, 102, 267-268.	1.0	0
80	Authorâ€™s Reply to Liu et al.: â€œPharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumabâ€• Clinical Pharmacokinetics, 2020, 59, 1645-1646.	3.5	0
81	Shiga Toxin/Verocytotoxin-ProducingEscherichia coliInfections: Practical Clinical Perspectives. , 0, , 297-319.		0